( fthe TGF-beta superfamily are known to...)Discovery's KL-4 Surfactant Technology Demonstrates Novel,Anti-Inflammatory Properties,Health

f the TGF-beta superfamily are known to induce fibrosis (scar tissue formation) in the lung. The authors concluded that Surfaxin suppressed two central members of the TGF-beta superfamily (BMP10 and BMP15), which could have implications in reducing inflammation and fibrosis (scarring) of the lung in a variety of pulmonary diseases.

Thomas H. Shaffer, MS.E, Ph.D., Director, Nemours Research Lung Center, commented, "These data are quite compelling and point towards a novel and potentially clinically impactful mechanism for Surfaxin in the treatment of several respiratory disorders."

Robert Segal, M.D., Senior Vice President & Chief Medical Officer of Discovery, commented, "Respiratory inflammation is a primary component of many lung diseases. It is well established that respiratory inflammatory mediators damage the cells that make surfactant. Our research and development strategy is focused on diseases in which respiratory inflammation plays an integral part in development of lung diseases such as Bronchopulmonary Dysplasia, Cystic Fibrosis, Acute Respiratory Failure, Accute Lung Injury and Chronic Obstructive Pulmonary Disease. These data support our hypothesis that KL-4 surfactants may be uniquely beneficial in reducing lung inflammation and preserving pulmonary function."

About KL-4 Surfactant

Discovery's surfactant product candidates, including Surfaxin, are engineered versions of natural human lung surfactant and contain a precision-engineered KL-4 peptide. KL-4 is a 21 amino acid protein-like substance that is designed to closely mimic the essential attributes of human surfactant protein B (SP-B), the surfactant protein most important for the proper functioning of the respiratory system. KL-4 surfactant has the potential to be precisely formulated as a liquid instillate, an aerosolized liquid or a dry powder to address various respiratory diseases affecting premature infants, children and adults.

About Surfaxin(r)

Su
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies
2. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
3. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
6. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
7. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
10. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
11. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology